Characterization and molecular docking study of cathepsin L inhibitory peptides (SnuCalCpIs) from Calotropis procera R. Br

Chang Woo Kwon1,5, Subin Yeo2,5 & Pahn-Shick Chang1,2,3,4*  

Propeptides, released from the autocatalytic activation of its zymogen, are potential inhibitors against proteases involved in cancer cell invasion and migration. Our research team previously obtained novel propeptides (SnuCalCpIs) from transcriptome analysis of the medicinal plant Calotropis procera R. Br. and reported them as promising candidates for cancer therapeutics due to their cathepsin L inhibition activity. In the present study, inhibitory activity among SnuCalCpIs was compared with inhibition efficiency and verified by in silico molecular docking analysis. Only SnuCalCpI03 and SnuCalCpI15, expressed in Escherichia coli, showed inhibitory activity against cathepsin L as competitive inhibitors, and the half-maximal inhibitory concentrations (IC50) values of 2.1 nM and 1.6 nM, respectively. They were stable below 70 °C, maintaining more than 90% inhibitory activity over a wide range of pH (2.0–10.0), except at the isoelectric point (pI). The template-based docking simulation models showed that SnuCalCpI02, SnuCalCpI12, and SnuCalCpI16 could not interact with the substrate-binding cleft of cathepsin L even though they possessed the same conserved domain. In contrast, SnuCalCpI03 and SnuCalCpI15 interacted with cathepsin L along the propeptide binding loop and substrate-binding cleft, resulting in obstruction of substrate access to the active site.

Proteolytic enzymes (also termed proteases, proteinases, and peptidases) hydrolyze peptide bonds in proteins and are critical for malignant tumor cell progression1. Lysosomal proteases such as cathepsins have emerged as potential effectors that change the tumor microenvironment by degrading various growth factors (chemokines and cytokines) and the extracellular matrix (ECM)2,3. Cathepsins are also involved in the detachment of cell–cell adhesion molecules and contribute to tissue invasion, and therefore represent a crucial class of proteases that promote cancer progression and metastasis4. Although many cathepsins have no effect or a tumor-promoting function in specific cancer types, cathepsin L has a unique ability to either suppress or enhance carcinogenesis in a context-dependent manner. Cathepsin L is often expressed at high levels in tumors5. In some instances, particularly in breast, pancreatic, and head and neck cancer, cathepsin L expression is a valuable biomarker with a negative prognostic indicator for patients’ time to relapse and overall survival6–8. Therefore, cathepsin L is regarded as an attractive target for inhibitor development as a potent therapeutic agent.

Various types of cathepsin L inhibitors have been investigated as cancer cures9–11. Among them, high-molecular-weight protein inhibitors have attracted interest as a potential alternative or adjunct therapy for the treatment of cancer invasion. Unlike chemical inhibitors that bind cysteine residues at the active site regardless of the type of enzyme, these protein inhibitors have higher enzyme selectivity resulting from stereospecificity of the protein–protein interaction occurring only at the specific enzyme surface. Cysteine protease propeptides, promising inhibitors released from the autocatalytic activation of its proenzyme, were obtained from Calotropis procera R. Br. and termed as SnuCalCpIs12. Among them, SnuCalCpI03 displayed remarkable inhibition of lung, colon, breast, pancreatic, and prostatic cancer cell invasion by interacting with cathepsin L secreted from cancer cells13. The propeptide chain bends along the propeptide binding loop of cathepsin L and covers the substrate-binding...
cleft, thereby blocking substrate access to the active site. However, the in-depth interaction between cathepsin L and SnuCalCpIs is not known.

A few protein–protein complex structures have been successfully determined and deposited in the Protein Data Bank (PDB) over the past few decades. However, the number of protein complexes in the PDB is still minimal compared with the number of individual protein molecules because of the high cost and technical difficulties in finding optimum conditions. As such, protein–protein docking simulation, which computationally predicts the interaction between two proteins, has played a crucial role in producing structural information for two different proteins and larger complexes. Computational docking methods designed for determining interactions between more flexible and larger peptide molecules are more suitable for the modeling than small-molecule-proteins. Template-based methods, in particular, usually yield higher-quality predictions if good templates are available.

In this study, we used six peptide inhibitors (SnuCalCpIs), obtained from Calotropis procera R. Br., which might inhibit cathepsin L activity, and compared their characteristics, e.g., inhibition efficiency, type, and stability. Furthermore, we used in silico molecular docking analysis to interpret the differences in inhibition activity between cathepsin L and SnuCalCpIs despite conserved domains in the SnuCalCpIs.

Materials and methods

Plant material. Calotropis procera R. Br., cultivated in Myanmar, was kindly gifted from 3M Korea Ltd. (Seoul, South Korea) and identified by Dr. Byoung-Cheorl Kang at Seoul National University. It was grown in a greenhouse at the agricultural experiment farm of Seoul National University (Suwon, South Korea). The experimental research of the plant material used in this study complies with relevant institutional, national, and international guidelines and legislation.

RNA extraction and cDNA synthesis. Total RNA was extracted from Calotropis procera R. Br. using an RNeasy® plant mini kit (Qiagen, Valencia, CA, USA). A young leaf of Calotropis procera R. Br. was ground in a liquid nitrogen medium, and RNA was extracted according to the manufacturer’s protocol. RNA was eluted with 30 μL of RNase-free water, and the RNA concentration was quantified using a NanoDrop spectrophotometer at a wavelength of 260 nm. Samples with RNA integrity values above 8.3 determined by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) were used. cDNA was synthesized with 5 μg of RNA using a PrimeScript” first-strand cDNA synthesis kit (Takara, Otsu, Japan). Synthesis of cDNA was carried out with RNase inhibitor, oligo dT primer, total RNA, 5X PrimeScript buffer, dNTP mixture, PrimeScript RTase and dNTP mixture.

Amplification of SnuCalCpI genes and construction of recombinant plasmids. SnuCalCpI genes (GenBank: GBHG01000000 and GBZK01000000) were amplified using first-strand cDNA and gene-specific primers (Table S1), including restriction sites (NdeI and XhoI) and In-Fusion HD cloning sites. The first-strand cDNA was screened according to the sequence identity (> 40%) with cathepsin L propeptide. PCR amplification was carried out as follows: 95 °C for 2 min; 95 °C for 30 s, 53 °C for 30 s, 72 °C for 60 s (27 cycles); 72 °C for 5 min. Duplicate PCR products were purified from 1% agarose gel electrophoresis using a QIAEX II® Gel Extraction Kit (Qiagen) and sequenced by an ABI 3730xl DNA analyzer. The purified PCR products were cloned with a linearized pET29b (+) vector, which was digested using NdeI and XhoI. The recombinant plasmid was then transformed into competent Escherichia coli (E. coli) DH5α cells and replicated, purified, and sequenced.

Expression and purification of SnuCalCpIs. The purified recombinant plasmid from competent E. coli DH5α cells was transformed into E. coli BL21 (DE3) Star competent cells for protein expression. A single colony grown on an LB agar plate containing 50 μg/mL kanamycin was cultured overnight in 5 mL LB broth containing 50 μg/mL kanamycin at 37 °C with shaking. A 2 mL volume of the overnight culture was inoculated into 200 mL of fresh LB medium with 50 μg/mL kanamycin and incubated at 37 °C with shaking until the optical density at 600 nm (OD600) was between 0.6 and 0.8. Subsequently, expression of the SnuCalCpI genes was induced by adding 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 20 °C for 12 h. After centrifugation at 10,000 xg for 10 min at 4 °C, the supernatant was added to the cell pellet resuspended in 50 mM Tris–HCl buffer (pH 8.0) with 300 mM NaCl and 10 mM imidazole. Sonication was carried out to disrupt the cell pellet with 10 cycles of 10 s pulse, 10 s pause, and 35% power. The cell lysates were separated into pellet and supernatant by centrifugation at 12,000 xg for 20 min and used for SDS-PAGE analysis. The His-tagged SnuCalCpIs in the supernatant was purified by Ni–NTA chromatography. The Ni–NTA column was washed with the lysis buffer (10 mM imidazole, 300 mM NaCl, and 50 mM Tris–HCl pH 8.0). Next, the supernatant was added to the Ni–NTA resin and gently mixed for 30 min at 4 °C. Unbound proteins were decanted, and the resin was washed with the washing buffer (20 mM imidazole, 300 mM NaCl, and 50 mM Tris–HCl pH 8.0). The adsorbed proteins were eluted using elution buffer (250 mM imidazole, 300 mM NaCl, and 50 mM Tris–HCl pH 8.0), and the eluent was dialyzed for inhibition assays.

Determination of inhibitory activity against papain. The inhibitory activity of SnuCalCpIs against papain (Sigma Co., Missouri, USA) was determined by measuring the residual enzyme activity towards N-α-Benzoyl-IMG-arginine-β-naphthylamide (BANA). The reaction mixture was prepared as follows: 3.6 μg/mL papain, 0–28.6 μg/mL SnuCalCpIs, 7.1 mM 2-mercaptoethanol, and 0.3 mM BANA in 71 mM sodium phosphate buffer, pH 6.0, containing 1.4 mM ethylenediaminetetraacetic acid (EDTA). The mixture was pre-incubated for 10 min at 37 °C without BANA. Then, the enzyme reaction was initiated by adding BANA dissolved in DMSO at 37 °C. The enzyme reaction was terminated by adding 1 mL of 0.06% (w/v) p-dimethylaminocinnamaldehyde/
ethanol and 1 mL of 2% (v/v) HCl/ethanol. The reactant was kept at room temperature for 30 min for color development, and the intensity of β-naphthylamine was measured at 540 nm using a spectrophotometer. The relative residual activity of papain was evaluated using the following equation:

\[
\text{Relative residual activity (\%) = } \frac{T^*}{T} \times 100
\]

where T denotes the OD_{540} in the absence of SnuCalCpIs, and T* is the OD_{540} in the presence of SnuCalCpIs.

**Determination of inhibitory activity against cathepsin L.** The inhibitory activity of SnuCalCpIs against cathepsin L (BioVision Inc., California, USA) was determined by measuring the residual enzyme activity towards Z-Phe-Arg-7-amino-4-methylcoumarin hydrochloride (Z-Phe-Arg-AMC)\(^{18}\). The reaction mixture was prepared as follows: 0.2 nM cathepsin L, 0–9.5 nM SnuCalCpIs, 10 mM dithiothreitol, and 0.6 µM Z-Phe-Arg-AMC in 100 mM sodium phosphate buffer, pH 6.0, containing 2 mM EDTA. The mixture was pre-incubated for 10 min at 30 °C without Z-Phe-Arg-AMC. Then, the enzyme reaction was initiated by adding Z-Phe-Arg-AMC. The activity of cathepsin L was determined by measuring the fluorescent intensity of AMC with excitation/emission peak wavelengths at 355/460 nm in a fluorometer. The relative residual activity of cathepsin L was evaluated using the following equation:

\[
\text{Relative residual activity (\%) = } \frac{T^*}{T} \times 100
\]

where T denotes the initial velocity in the absence of SnuCalCpIs and T* is that in the presence of SnuCalCpIs.

**Enzyme inhibition kinetics.** The inhibition mode of SnuCalCpIs was determined from its inhibitory activity against cathepsin L. SnuCalCpIs (0, 20, and 40 nM) were mixed with cathepsin L, and the mixtures were pre-incubated for 10 min at 30 °C. Inhibitory activity was measured with the addition of each substrate at concentrations ranging from 0.5 to 2.0 µM. The kinetic parameters and the mode of enzyme inhibition were determined from Lineweaver–Burk plots and the initial velocities of cathepsin L activity\(^{19}\).

**Effects of temperature and pH.** The effects of temperature and pH on the inhibitory activity were determined by comparing relative inhibitory activity against cathepsin L. The thermostability of the inhibitor samples was evaluated by measuring the residual inhibitory activity after incubation in temperatures ranging from 30 to 100 °C for 30 min in 50 mM Tris–HCl buffer (pH 8.0). For the determination of pH stability, inhibitor samples were incubated in 100 mM glycine–HCl buffer over a pH range of 2.0–3.0, 100 mM sodium acetate buffer over a pH range of 4.0–5.0, 100 mM sodium phosphate buffer at pH 6.0, and 100 mM glycine–NaOH buffer over a pH range of 7.0–8.0, and 100 mM glycine–NaOH buffer over a pH range of 9.0–10.0 at 4 °C for 24 h.

**Circular dichroism.** Far-ultraviolet (UV) (190–260 nm) circular dichroism (CD) spectra were obtained from the CD spectrometer (ChirascanTM-plus, Applied Photophysics, Ltd., Leatherhead, Surrey, UK) and temperature-regulated cells (25 °C) with 0.5 mm path and 1.0 nm bandwidth. The spectra were taken at pH 4.0, 5.0, and 6.0 in media mentioned above.

**In silico molecular docking.** Since suitable templates for homology modeling were stored in the PDB, the amino acid sequences of mature cathepsin L and SnuCalCpIs were submitted to SWISS-Model (https://www.swissmodel.expasy.org) (Table S2). One template from the identification results was used as the guide based on its similarity and identity. The three-dimensional (3D) structures of SnuCalCpIs were built based on selected templates and visualized using Pymol software (version 2.5.2). The quality of the model was assessed by Ramachandran plots and QMEANDisCo Global (high numbers between 0 and 1 indicate high quality). Lastly, the in silico molecular docking simulation of mature cathepsin L and SnuCalCpIs was performed by HDOCK (http://www.hdock.phys.hust.edu.cn) which provides both template-based modelling and ab initio free docking\(^{20}\).

**Results and discussion**

**Molecular cloning and sequencing of SnuCalCpI genes.** After 1st strand cDNA synthesis, the eight DNA sequences of SnuCalCpI genes including SnuCalCpI02, SnuCalCpI03, SnuCalCpI08, SnuCalCpI12, SnuCalCpI14, SnuCalCpI15, SnuCalCpI16, and SnuCalCpI17 were amplified using specifically designed primers. Amplified SnuCalCpI gene fragments with sizes ranging from 320 to 380 bp were extracted, cleaned, and cloned into pET29b (+) vectors. Recombinant pET29b plasmids were transformed into competent E. coli DH5α cells. The DNA sequence of SnuCalCpI genes from recombinant plasmids was sequenced and verified by sequence alignment with cDNA sequences from *Calotropis procera* R. Br.

A multiple sequence alignment of SnuCalCpI genes was performed with a papain propeptide sequence (GenBank: AAB02650) and a human cathepsin L propeptide sequence (GenBank: AAH12612.1) to investigate sequence similarities and conserved regions (Fig. S2). The results showed that SnuCalCpIs consist of three different α-helices with helix-hinge-helix motifs commonly found in cathepsin L propeptides and papain propeptides\(^{21}\). In particular, the highly conserved regions, 'ERFNIN (EXXXRXXXFXXNXXXIXXXN)' motif which is located in the long α-helix II and constitutes a major part of the propeptide, and 'GNFD (GNNXFXD)' motif which is present at the kink between the β-sheet and the short α-helix III hindering the exposure of the interdomain cleft, among SnuCalCpIs indicate that they belong to a papain-like cysteine protease family\(^{22}\). The presence of the
ERFNIN-GNFD motif also suggests that SnuCalCpIs can be classified as Inhibitor I29 according to MEROPS, which runs through the substrate-binding site and blocks substrate access. As such, SnuCalCpIs potentially inhibits the activity of human cathepsin L23,24.

Expression of SnuCalCpIs in the *E. coli* system and purification. The recombinant plasmid for each SnuCalCpI gene was transformed into *E. coli* BL21(DE3) for protein expression. SDS-PAGE was used to analyze the solubility of the proteins for further study. The SDS-PAGE results in Fig. S1 displayed that water-soluble SnuCalCpI02, SnuCalCpI03, SnuCalCpI12, SnuCalCpI15, and SnuCalCpI16 were expressed at a high level. On the other hand, SnuCalCpI08, SnuCalCpI14, and SnuCalCpI17 could not be expressed under the selected conditions. Thus SnuCalCpI08, SnuCalCpI14, and SnuCalCpI17 were excluded in the subsequent experiments. Expressed proteins were purified by Ni–NTA affinity chromatography, and their molecular weights ranging from 13 to 16 kDa were confirmed by SDS-PAGE analysis (Fig. S3). It is not clear why overexpression in the *E. coli* system did not occur. However, it may be possible to achieve overexpression if we optimize expression conditions, e.g., codon usage, *E. coli* strain, temperature, and inducer concentration25.

Inhibitory activity against papain and cathepsin L. Proteases, such as actinidain, caricain, cathepsin L, and ficain belong to the papain family C1 and are part of the clan CA cysteine proteases. They have zymogens and mature structures similar to those of papain and generally possess Cys25 and His159 residues in the catalytic dyad, and Gln19 and Asn175 residues in the active site that form the oxyanion hole and orientate the imidazole ring of the catalytic His. Papain was used as a representative enzyme of clan CA due to its well-known mature structure for understanding the inhibitory activity of SnuCalCpIs against papain-like cysteine protease. As a result, only SnuCalCpI03 and SnuCalCpI15 inhibited papain activity, whereas SnuCalCpI02, SnuCalCpI12, and SnuCalCpI16 did not show any inhibition against papain even though they have common conserved regions (Fig. 1). Therefore, we assumed that SnuCalCpI03 and SnuCalCpI15 would be effective inhibitors against papain-like cysteine proteases and consequently expected them to inhibit cathepsin L.

Inhibitory activity of SnuCalCpIs against cathepsin L was confirmed and compared by obtaining half-maximal inhibitory concentration (IC₅₀) values. As shown in the result against papain, only SnuCalCpI03 and SnuCalCpI15 inhibited the activity of cathepsin L (Fig. 2). IC₅₀ values of 2.1 nM and 1.6 nM were determined from
SnuCalCpI03 and SnuCalCpI15, respectively, by plotting fitted curves of residual activity of cathepsin L. Their inhibition efficiency implies that the structures are more suitable for cathepsin L than papain.

**Types of cathepsin L inhibition.** A kinetic study of SnuCalCpI inhibition on cathepsin L was conducted to identify the mode of inhibition. A double reciprocal Lineweaver–Burk plot, widely used for enzyme kinetics, was adapted to elucidate the inhibition characteristics of SnuCalCpI03 and SnuCalCpI15. In the presence of SnuCalCpI03 and SnuCalCpI15, the slopes of the straight lines in the double reciprocal plot increased with increasing concentrations of SnuCalCps. $K_m$ values at the x-intercept increased, but $V_{max}$ values at the y-intercept did not change with the slope (Fig. 3). The concentrations of SnuCalCps affected both the horizontal axis and slope of the Lineweaver–Burk plot, indicating that they are competitive inhibitors.

The peptide inhibitors compete with the substrate for binding at the active site of cathepsin L, and consequently inactivate cathepsin L through reversible and non-covalent interactions. The weak binding of the peptide inhibitor formed from the non-covalent interactions may be desirable for specific enzyme targets as it has a higher selectivity and lower off-target toxicity than covalent inhibitors.22 Specifically, reversible competitive peptide inhibitors recognize specific amino acid residues on the enzyme surface and active site through hydrogen bonding, hydrophobic, electrostatic, and van der Waals interaction.26 Therefore, the inhibitor can interact selectively with a specific enzyme. On the other hand, some irreversible covalent inhibitors occasionally form a covalent bond with reactive molecules, e.g., cysteine and serine, even when they are not located in the active site of the target enzyme, resulting in immunological response or cell damage.27

**Thermal and pH stability.** To investigate their thermal stability, SnuCalCpI03 and SnuCalCpI15 were incubated at 30–100 °C for 30 min and cooled at 4 °C. Both inhibitors were stable and recovered more than 90% of their original inhibitory activity between 30 and 70 °C (Fig. 4). However, the residual inhibitory activity was reduced to 70% after incubation at 80–100 °C. These results imply that the thermal unfolding of the inhibitors was partial and reversible due to their intra-helical salt bridges or simple and compact tertiary structure. However, the lack of disulfide bonds might have decreased their thermal stability.
The pH stability profile showed that SnuCalCpI03 and SnuCalCpI15 are stable over the pH range from 2.0 and 10.0, except for 5.0 and 7.0, respectively, by maintaining more than 90% of its original inhibitory activity (Fig. 5). The negatively or positively charged structures of the peptide in acidic and alkaline conditions could be refolded into native structures because it remained in a molten globule state. However, a significant loss of inhibitory activity was found near the isoelectric point (pI) of 5.2 and 6.9 for SnuCalCpI03 and SnuCalCpI15, respectively. Therefore, it was concluded that they could not be restored after they precipitate at the pI. Although it seems that these peptide inhibitors are composed of three α-helices and one β-sheet, which are not considered sophisticated, there are several crucial interactions to maintain the globular fold: (i) hydrophobic core formation between α-helixes; (ii) salt bridges between α-helix and β-sheet strand; and (iii) a hydrophobic minicore between α-helix and cathepsin L28. The far-UV CD spectra of SnuCalCpI03 over the pH range from 4.0 to 6.0 supported the above mentioned loss of interactions and inhibitory activity near the pI (Fig. 6). At pH 6.0, an intense positive band at 193 nm, an intense negative band at 208 nm, and a shoulder at 218 nm suggest a high proportion of amino acid residues integrated into α-helical secondary structures. The CD spectrum at pH 4.0 was similar to that at pH 6.0 except that there was no shoulder at 218 nm due to the secondary structure alteration induced by acidification. In contrast, the CD spectrum at pH 5.0 did not show any distinct band intensities over the wavelength range from 190 to 230 nm unlike those at pH 4.0 and 6.0.

From the stability test results and far-UV CD spectra, it was expected that SnuCalCpI03 and SnuCalCpI15, which are stable over a wide range of temperatures and pHs, except at the pI, could be stored and applied in diverse environments.

**In silico molecular docking analysis.** In *silico* molecular docking simulation of mature cathepsin L and SnuCalCpIs was conducted to analyze why some SnuCalCpIs have inhibitory activity against cathepsin L, and others have not, even though they have ERFNIN and GNFD motifs which are important elements for inhibiting activity of papain-like cysteine proteases. We performed molecular docking analysis with template-based prediction because activation of the proenzyme does not cause critical conformational changes for the mature cysteine protease and its propeptide28. In addition, the quantitative docking scores including HDOCK score and ligand rmsd (Å) from template-based modeling were compared with those of *ab initio* free docking. Before proceeding with the simulations, the quality of the template-based models generated by SWISS-MODEL was
analyzed and compared. The analysis with QMEANDisCo and favored regions of Ramachandran plots demonstrated good quality of all models except SnuCalCpI16 (Table 1).

The best prediction models out of ten obtained from HDOCK were shown in Fig. 7 and docking scores of them were enumerated in Table 2. The simulation models showed that only SnuCalCpI03 and SnuCalCpI15 blocked the active site cleft of cathepsin L, which verifies inhibitory activity of them, although the quantitative docking score and ligand rmsd (Å) did not show significant difference among the predicted protein–protein complexes. The SnuCalCpI03 and cathepsin L interactions occurred in three propeptide binding loops of cathepsin L: surface formed by the Thr 14-Cys 21, Phe 143-Gly 149, and Trp 189-Gly 194. The presence of α-helix III is considered not essential for inhibitory activity but plays an important role in maintaining cathepsin L-SnuCalCpI03 complex. On the other hand, α-helix II and adjacent amino acid residues are essential and stabilize the structure by forming a hairpin structure and allow it to interact with the propeptide binding loop through hydrogen bonds and hydrophobic interactions. Thereby, α-helix III can interact with amino acid residues in the vicinity of catalytic dyad (Cys25 and His163) and block substrate access. The inhibition mode of SnuCalCpI15 was similar to that of SnuCalCpI03, but it was slightly different because it lacked C-terminal region contributing little to overall inhibition. To cross-check simulation results from template-based models, \textit{ab initio} free docking was conducted. However, it was impossible to compare the simulation results with those of sequence-based docking because the protein–protein interaction occurred at a great distance from the catalytic dyad.

Conclusions
This study evaluated the inhibitory activity of SnuCalCpIs against cathepsin L, which plays a crucial role in cancer cell migration through ECM degradation. The inhibition mechanism was investigated by adopting a bioinformatics approach. Only SnuCalCpI03 and SnuCalCpI15 out of five expressed SnuCalCpIs could inhibit cathepsin L activity by blocking substrate access to the active site of cathepsin L, although all the SnuCalCpIs have highly conserved domains and form α-helix structures. \textit{In silico} protein–protein docking simulations, especially structure-based modeling, can be useful to validate experimental or predicted results.

| Model      | GMQE | QMEANDisCo global | Ramachandran favored (%) |
|------------|------|-------------------|--------------------------|
| SnuCalCpI02| 0.49 | 0.57 ± 0.09       | 94.68                    |
| SnuCalCpI03| 0.50 | 0.65 ± 0.09       | 87.23                    |
| SnuCalCpI12| 0.49 | 0.69 ± 0.09       | 90.24                    |
| SnuCalCpI15| 0.46 | 0.69 ± 0.10       | 97.50                    |
| SnuCalCpI16| 0.08 | 0.26 ± 0.12       | 84.85                    |

Table 1. Quality assessment scores of modeled structures.

Figure 6. Far-UV CD spectra of SnuCalCpI03 at pH 4.0, 5.0, and 6.0.
Figure 7. Protein–protein docking simulation of cathepsin L and SnuCalCpIs. (a) cathepsin L-SnuCalCpI02 complex, (b) cathepsin L-SnuCalCpI03 complex, (c) cathepsin L-SnuCalCpI12 complex, and (d) cathepsin L-SnuCalCpI15 complex. The enzyme and inhibitor were represented in gray and lightpink, respectively. The catalytic dyad (Cys25 and His163) and interface residues were illustrated in red and palegreen, respectively. The protein–protein complex was visualized using Pymol software (version 2.5.2).

Table 2. Quantitative docking scores for cathepsin L-SnuCalCpI complex.

| Model   | Structure-based docking | Sequence-based docking |
|---------|-------------------------|------------------------|
|         | HDOCK score | RMSD (Å) | HDOCK score | RMSD (Å) |
| SnuCalCpI02 | 250.97       | 50.57    | −255.83     | 175.39    |
| SnuCalCpI03 | 196.35       | 71.93    | −206.32     | 44.47     |
| SnuCalCpI12 | 202.45       | 40.93    | −285.44     | 198.54    |
| SnuCalCpI15 | 236.99       | 80.44    | −212.34     | 32.52     |

References
1. Rakash, S., Rana, F., Rafiq, S., Masood, A. & Amin, S. Role of proteases in cancer: a review. Biotechnol. Mol. Biol. Rev. 7, 90–101 (2012).
2. Mason, S. D. & Joyce, J. A. Proteolytic networks in cancer. *Trends Cell Biol.* **21**, 228–237 (2011).
3. Tomovski, M. & Turk, B. Cysteine cathepsins and extracellular matrix degradation. *Biochim. Biophys. Acta Gen. Subj.* **1840**, 2560–2570 (2014).
4. Olson, O. C. & Joyce, J. A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. *Nat. Rev. Cancer* **15**, 712–729 (2015).
5. Sudhan, D. R. & Siemann, D. W. Cathepsin L targeting in cancer treatment. *Pharmacol. Ther.* **155**, 105–116 (2015).
6. Singh, N. et al. Plasma cathepsin L: a prognostic marker for pancreatic cancer. *World J. Gastroenterol.* **20**, 17532 (2014).
7. Thomssen, C. et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. *Cancer Clin. Cancer Res.* **1**, 741–746 (1995).
8. Macabero-Ong, M. et al. Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression. *Oral Oncol.* **39**, 638–647 (2003).
9. Zaic, I., Sever, N., Bervar, A. & Lah, T. T. Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. *Cancer Lett.* **187**, 185–190 (2002).
10. Sudhan, D. R., Rabaglini, M. B., Wood, C. E. & Siemann, D. W. Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. *Clin. Exp. Metastasis* **33**, 461–473 (2016).
11. Rebbaa, A. et al. The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. *Anticancer Res.* **29**, 4473–4481 (2009).
12. Kwon, C. W. et al. Cysteine protease profiles of the medicinal plant Calotropis procera R. Br. revealed by de novo transcriptome analysis. *PLoS One* **10**, e0119328 (2015).
13. Kwon, C. W. et al. Molecular cloning and anti-invasive activity of cathepsin L propeptide-like protein from *Calotropis procera* R. Br. against cancer cells. *J. Enzyme Inhib. Med. Chem.* **33**, 657–664 (2018).
14. Pagadala, N. S., Syed, K. & Tuszynski, J. Software for molecular docking: a review. *Biophys. Rev.* **9**, 91–102 (2017).
15. Chemy, M. et al. Protein–peptide docking: opportunities and challenges. *Drug Discov. Today* **23**, 1530–1537 (2018).
16. Porter, K. A., Desta, I., Kozakov, D. & Vajda, S. What method to use for protein–protein docking? *Curr. Opin. Struct. Biol.* **55**, 1–7 (2019).
17. Abe, M., Abe, K., Iwabuchi, K., Domoto, C. & Arat, S. Corn cystatin I expressed in *Escherichia coli*: Investigation of its inhibitory profile and occurrence in corn kernels. *J. Biochem.* **116**, 488–492 (1994).
18. Barrett, A. J. & Kirschke, H. Cathepsin B, cathepsin H, and cathepsin L. *Methods Enzymol.* **80**, 535–561 (1981).
19. Lineweaver, H. & Burk, D. The determination of enzyme dissociation constants. *J. Am. Chem. Soc.* **56**, 658–666 (1934).
20. Yan, Y., Hao, H., He, J. & Huang, S.-Y. The HDOCK server for integrated protein–protein docking. *Nat. Protoc.* **15**, 1829–1852 (2020).
21. Verma, S., Dixit, R. & Pandey, K. C. Cysteine proteases: Modes of activation and future prospects as pharmacological targets. *Front. Pharmacol.* *https://doi.org/10.3389/fphar.2016.00107* (2016).
22. Wiederanders, B., Kaulmann, G. & Schilling, K. Functions of propeptide parts in cysteine proteases. *Curr. Protein Pept. Sci.* **4**, 309–326 (2003).
23. Roy, S., Choudhury, D., Aich, P., Dattagupta, J. K. & Biswas, S. The structure of a thermostable mutant of pro-papain reveals its activation mechanism. *Acta Crystallogr. Sect. D Biol. Crystallogr.* **68**, 1591–1603 (2012).
24. Martinez, M. & Diaz, I. The origin and evolution of plant cystatins and their target cysteine proteinases indicate a complex functional relationship. *BMC Evol. Biol.* **8**, 1–12 (2008).
25. Francis, D. M. & Page, R. Strategies to optimize protein expression in *E. coli*. *Curr. Protoc. Protein Sci.* **61**, 5.24.21-25.24.29 (2010).
26. Cygler, M. & Mort, J. Proregion structure of members of the papain superfamily. Mode of inhibition of enzymatic activity. *Biochimie* **79**, 645–652 (1997).
27. Johnson, D. S., Weerapana, E. & Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. *Biochimie* **86**, 949–964 (2010).
28. Coughambe, R. et al. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. *EMBO J.* **15**, 5492–5503 (1996).

**Acknowledgements**

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (NRF-2020R1A2B5B01002596) and “Cooperative Research Program for Agriculture Science & Technology Development (Project No. PJ01589402)” provided by Rural Development Administration, Republic of Korea.

**Author contributions**

C. W. K.: Methodology, Supervision, Validation, Formal analysis, Data curation, Visualization, Investigation, Software, Writing—original draft. S. Y.: Conceptualization, Methodology, Investigation, Validation, Writing—original draft. P.-S. C.: Project administration, Funding acquisition, Writing—review & editing, Supervision.

**Declarations**

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1038/s41598-022-09854-x](https://doi.org/10.1038/s41598-022-09854-x).

**Correspondence** and requests for materials should be addressed to P.-S.C.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
